Catalyst Pharmaceuticals
Stock Forecast, Prediction & Price Target
Catalyst Pharmaceuticals Financial Estimates
Catalyst Pharmaceuticals Revenue Estimates
Catalyst Pharmaceuticals EBITDA Estimates
Catalyst Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $140.83M N/A | $214.20M 52.09% | $398.20M 85.90% | Avg: $542.83M Low: $528.13M High: $558.34M avg. 36.32% | Avg: $610.95M Low: $597.84M High: $627.78M avg. 12.54% | Avg: $715.65M Low: $700.29M High: $735.36M avg. 17.13% | Avg: $675.58M Low: $661.08M High: $694.19M avg. -5.59% |
Net Income
% change YoY
| $39.48M N/A | $83.07M 110.42% | $71.41M -14.04% | Avg: $161.00M Low: $135.36M High: $153.56M avg. 125.46% | Avg: $185.05M Low: $154.70M High: $182.00M avg. 14.93% | Avg: $177.45M Low: $172.50M High: $183.80M avg. -4.10% | Avg: $191.10M Low: $185.77M High: $197.94M avg. 7.69% |
EBITDA
% change YoY
| $52.38M N/A | $101.83M 94.40% | $119.69M 17.53% | Avg: $196.13M Low: $190.82M High: $201.73M avg. 63.86% | Avg: $220.74M Low: $216.00M High: $226.82M avg. 12.54% | Avg: $258.57M Low: $253.02M High: $265.69M avg. 17.13% | Avg: $244.09M Low: $238.85M High: $250.82M avg. -5.59% |
EPS
% change YoY
| $0.38 N/A | $0.8 110.52% | $0.67 -16.25% | Avg: $1.29 Low: $1.19 High: $1.35 avg. 92.23% | Avg: $1.48 Low: $1.36 High: $1.6 avg. 14.90% | Avg: $1.56 Low: $1.52 High: $1.62 avg. 5.40% | Avg: $1.68 Low: $1.63 High: $1.74 avg. 7.69% |
Operating Expenses
% change YoY
| $66.56M N/A | $77.97M 17.13% | $259.42M 232.71% | Avg: $183.67M Low: $178.69M High: $188.91M avg. -29.20% | Avg: $206.71M Low: $202.28M High: $212.41M avg. 12.54% | Avg: $242.14M Low: $236.94M High: $248.81M avg. 17.13% | Avg: $228.58M Low: $223.68M High: $234.88M avg. -5.59% |
FAQ
What is Catalyst Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 35.99% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is 135.36M, average is 161.00M and high is 153.56M.
What is Catalyst Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 15.10% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $528.13M, average is $542.83M and high is $558.34M.
What is Catalyst Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 30.06% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is $1.19, average is $1.29 and high is $1.35.
What is the best performing analyst?
In the last twelve months analysts have been covering Catalyst Pharmaceuticals stock. The most successful analyst is Joseph Catanzaro whose win rate is 100%. He has correctly predicted 1/1 price targets.